Phase II trial of diaziquone in advanced ovarian carcinoma. European Organization for Research on Treatment of Cancer Early Clinical Trials Group.
D000328:Adult; D000368:Aged; D001388:Aziridines / Q000009:adverse effects / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D016227:Benzoquinones; D003536:Cystadenocarcinoma / Q000188:drug therapy / Q000473:pathology; D004341:Drug Evaluation; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014839:Vomiting / Q000139:chemically induced
D001388:Aziridines; D001389:Azirines; D016227:Benzoquinones; C029108:diaziquone